EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance

M Alexandra Lake iD, Kristin N Adams, Feilin Nie, Elaine Fowler, Amit K Verma, Silvia Dei, Elisabetta Teodori, David R Sherman, Paul H Edelstein iD, David R Spring iD, Mark Troll, Lalita Ramakrishnan iD

Proceedings of the National Academy of Sciences · 2023

DOI: 10.1073/pnas.2215512120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von M Alexandra Lake und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, CB2 …. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis treatment requires months-long combination chemotherapy with multiple drugs, with shorter treatments leading to relapses. A major impediment to shortening treatment is that Mycobacterium tuberculosis becomes tolerant to the administered drugs, starting early after infection and within days of infecting macrophages. Multiple lines of evidence suggest that macrophage-induced drug tolerance is mediated by mycobacterial drug efflux pumps. Here, using assays to directly measure drug efflux, we find that M. tuberculosis transports the first-line antitubercular drug rifampicin through a proton gradient-dependent mechanism. We show that verapamil, a known efflux pump inhibitor, which inhibits macrophage-induced rifampicin tolerance, also inhibits M.tuberculosis rifampicin efflux. As with macrophage-induced tolerance, the calcium channel-inhibiting property of verapamil is not required for its inhibition of rifampicin efflux. By testing verapamil analogs, we show that verapamil directly inhibits M. tuberculosis drug efflux pumps through its human P-glycoprotein (PGP)-like inhibitory activity. Screening commonly used drugs with incidental PGP inhibitory activity, we find many inhibit rifampicin efflux, including the proton pump inhibitors (PPIs) such as omeprazole. Like verapamil, the PPIs inhibit macrophage-induced rifampicin tolerance as well as intramacrophage growth, which has also been linked to mycobacterial efflux pump activity. Our assays provide a facile screening platform for M. tuberculosis efflux pump inhibitors that inhibit in vivo drug tolerance and growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisTuberculosisHumansRifampinProton Pump InhibitorsAntitubercular AgentsVerapamilMacrophagesDrug ToleranceBacterial ProteinsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

efflux pump inhibitorsmycobacterial efflux pumpsproton pump inhibitorstuberculosis rifampicin toleranceverapamil

Substanzen

RifampinProton Pump InhibitorsAntitubercular AgentsVerapamilBacterial Proteins

Autor:innen und Institutionen

  • Molecular Immunity Unit, Cambridge Institute of Therapeutic Immunology and Infectious Diseases, Department of Medicine, University of Cambridge, CB2 0AW Cambridge, UK.
  • Medical Research Council Laboratory of Molecular Biology, CB2 0QH Cambridge, UK.
  • Department of Microbiology, University of Washington, Seattle 98195.
  • Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK.
  • Department of Neuroscience, Psychology, Drug Research and Child Health - Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, 50019 Sesto Fiorentino (FI), Italy.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.

ORCID-Profile: M Alexandra Lake, Paul H Edelstein, David R Spring, Lalita Ramakrishnan

Förderung

  • NIAID NIH HHS
  • Wellcome Trust

Zitieren

APA

Lake, M. A., Adams, K. N., Nie, F., Fowler, E., Verma, A. K., Dei, S., Teodori, E., Sherman, D. R., Edelstein, P. H., Spring, D. R., Troll, M., & Ramakrishnan, L. (2023). The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2215512120

Vancouver

Lake MA, Adams KN, Nie F, Fowler E, Verma AK, Dei S, et al. The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2215512120

BibTeX
@article{Lake2023,
  author = {Lake, M Alexandra and Adams, Kristin N and Nie, Feilin and Fowler, Elaine and Verma, Amit K and Dei, Silvia and Teodori, Elisabetta and Sherman, David R and Edelstein, Paul H and Spring, David R and Troll, Mark and Ramakrishnan, Lalita},
  title = {The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2215512120}
}
Kostenlos starten →